

BMS 433796

Catalog No: tcsc0661

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Specifications

CAS No:

935525-13-6

Formula:

 $\mathsf{C}_{19}\mathsf{H}_{16}\mathsf{F}_{2}\mathsf{N}_{4}\mathsf{O}_{4}$

Pathway: Stem Cell/Wnt;Neuronal Signaling

Target:

γ-secretase;γ-secretase

Purity / Grade:

Solubility:

10 mM in DMSO

Observed Molecular Weight:

402.35

Product Description

BMS 433796 is a γ -secretase inhibitor with A β lowering activity in a transgenic mouse model of Alzheimer\'s disease.

IC50 & Target: γ -secretase^[1]


In Vitro:

Copyright 2021 Taiclone Biotech Corp.



BMS-433796 cause a concentration-dependent decrease in $[{}^{3}H]IN973$ binding, with IC₅₀ value of 1.2 nM, very similar to the IC₅₀ values for inhibition of Aβ40 in human embryonic kidney cells overexpressing the Swedish mutation of APP of 0.8 nM, respectively, and for inhibition of Aβ42 of 0.4 nM, respectively^[2].

In Vivo: BMS 433796 is characterized in pharmacokinetic studies in male Sprague-Dawley rats. Following a 10-min intravenous infusion at 2.3 µmol/kg in PEG-400, the total body clearance of 40 is 5.2 ± 0.82 mL/min/kg (means±SEM; n=3), indicating low clearance. The apparent terminal elimination half-life is 4.6 ± 0.48 h. Oral administration of a PEG-400 suspension at 35 µmol/kg shows an oral bioavailability of 31% with prolonged absorption. BMS 433796 has satisfactory metabolic stability in human liver microsomal preparations and is not an inhibitor of human CYPs (IC₅₀>100 µM)^[1]. Brain Aβ40 is reduced as a result of administering BMS-433796 in a dose-dependent manner, with ED₅₀ value of 2.4 mg/kg, respectively^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.